Psoriasis Clinical Trials in Columbus
View 15 new treatments for Psoriasis in Columbus, OH. Every day, Power helps hundreds of Psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Bexley + 2 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Bexley + 1 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
Certolizumab Pegol for Plaque Psoriasis
UCB Biopharma Clinic, Marion + 1 more
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
UCB Cares
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Columbus + 2 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Guselkumab for Psoriasis
Janssen Clinic, Bexley + 2 more
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Guselkumab for Plaque Psoriasis
Janssen Clinic, Bexley + 2 more
This trial is testing guselkumab, a medication that targets the immune system, on people with moderate plaque psoriasis affecting small areas and special sites. The drug helps reduce inflammation and rapid skin cell growth. Guselkumab has been approved for the treatment of moderate-to-severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
TAK-279 for Psoriasis
Takeda Clinic, Bexley + 1 more
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Study Director
Study Director
LY3972406 for Psoriasis
Eli Lilly Clinic, Columbus + 2 more
This trial is testing a new medication called LY3972406 to see if it can help adults with moderate-to-severe plaque psoriasis. The goal is to find out if it works well and is safe to use. Plaque psoriasis causes red, scaly patches on the skin, and this medication aims to reduce these symptoms.Show More
Recruiting
Phase 2
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 on - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TLL018 Tablets for Plaque Psoriasis
Hangzhou Highlightll Clinic, Columbus + 1 more
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.Show More
Recruiting
Phase 2
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Nivolumab for Cancer
Research Clinic, Columbus + 1 more
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.Show More
Recruiting
No Placebo Trial
Phase 1
Est. 6 - 12 Weeks
Hussein A Tawbi
Principal Investigator
Page 1 of 2
Frequently Asked Questions
Explore related conditions